Sign in Subscribe
Pharmaceutical industry

Tradjenta Tablets Now Available by Prescription in the United States

Strategic Insights

— 2 min read

Tradjenta tablets, developed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company, are now available in pharmacies across the US. The medication was approved by the FDA on May 2, 2011, as a treatment for type 2 diabetes in adults, taken along with diet and exercise. Tradjenta should not be used in patients with type 1 diabetes or diabetic ketoacidosis. The wholesale acquisition price for Tradjenta is $6.77 per tablet, and a Savings Card Program is available for patients who qualify, offering up to $150 in savings per 30-day supply.

Key Takeaways:

  • Tradjenta tablets, developed by Boehringer Ingelheim and Eli Lilly, are now available in pharmacies across the US.
  • The medication was approved by the FDA on May 2, 2011, as a treatment for type 2 diabetes in adults, taken along with diet and exercise.
  • Tradjenta should not be used in patients with type 1 diabetes or diabetic ketoacidosis.
  • The wholesale acquisition price for Tradjenta is $6.77 per tablet.
  • A Savings Card Program is available for patients who qualify, offering up to $150 in savings per 30-day supply.
  • Patients are not eligible if prescriptions are paid in part or full by any state or federally funded programs.
  • The Boehringer Ingelheim Cares Foundation Patient Assistance Programs make Boehringer Ingelheim medicines, including Tradjenta, available free of charge to patients who are without pharmaceutical insurance coverage and meet certain household income levels.
  • Tradjenta belongs to a class of prescription medications called dipeptidyl peptidase-4 (DPP-4) inhibitors and is the first member of its class to be approved at one dosage strength (5 mg, once daily).
  • With Tradjenta, no dose adjustment is recommended for patients with kidney or liver impairment.
  • It is a tablet that can be taken with or without food and lowers blood sugar in a glucose-dependent manner by increasing incretin levels.
  • Tradjenta was approved based on a clinical trial program that included approximately 4,000 adults with type 2 diabetes.
  • The medication showed statistically significant A1C reductions of up to 0.7 percent when used as monotherapy (compared to placebo) and when used in combination with metformin, sulfonylurea, and metformin plus sulfonylurea.

Statistics:

  • May 2, 2011: The date when Tradjenta was approved by the FDA.
  • $6.77: The wholesale acquisition price for Tradjenta per tablet.
  • Up to $150: The maximum savings offered by the Savings Card Program per 30-day supply for eligible cash-paying patients without commercial prescription coverage.
  • 24 months: The duration of the Savings Card Program.
  • 4,000: The approximate number of adults with type 2 diabetes included in the clinical trial program for Tradjenta.
  • 0.7 percent: The statistically significant A1C reductions when Tradjenta was used as monotherapy compared to placebo.
  • 0.6, 0.5, and 0.6 percent: The significant A1C reductions when Tradjenta was used in combination with metformin, sulfonylurea, and metformin plus sulfonylurea, respectively, compared to placebo.

Sources:

  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • U.S. Food and Drug Administration (FDA)
  • Clinical Trials Week editors
  • NewsRx.com

Read more